Fe-59 is an isotope of iron. It has a half-life of 44.5 days and decays by emitting a beta particle. In medicine, ferrous citrate Fe 59 is indicated, by intravenous administration, to determine various parameters of the kinetics of iron metabolism, including plasma iron clearance, plasma iron turnover rate, and the utilization of iron in new red blood cells. An oxidized form of iron cation, ferric cation Fe59, is also used to study the processes of iron metabolism.

Butetamate is a cough suppressant. It exerts antispasmodic, bronchodilator and anticholinergic properties.

Oxeladin citrate is a cough suppressant, is a highly potent and effective drug used to treat all types of cough of various etiologies. Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. Oxeladine is a component of antitussive drug, Altussan, approved in Philippines.

Cetiedil is effective potassium channel blocker used as a peripheral vasodilator to treat patients with painful crises in sickle cell anemia and pain in the extremities caused by an arterial disease. Known pharmacological properties of the drug include vascular smooth muscle relaxation, inhibition of phosphodiesterase with the consequent increase in circulating cyclic AMP concentration, blockade of the effect of bradykinin and serotonin, analgesia, inhibition of platelet aggregation and the decrease of plasma and blood viscosity and plasma fibrinogen level. The antisickling effect of cetiedil is explained mainly in the light of the changes it induces in the activities of membrane-bound ATPases and the permeability properties of the erythrocyte membrane to cations and anions.

Butamirate (or brospamin) is a medicine used for the symptomatic treatment of non-productive (dry) cough. Butamirate is centrally acting cough suppressant which is neither chemically nor pharmacologically related to opium alkaloids. In addition to its antitussive effect, Butamirate also decreases the airway resistance. Butamirate is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with sustain release tablet. Butamirate is extremely protein bound and Plasma elimination half-life is about 13 hours. Butamirate is indicated in acute cough of any etiology, pre and post operative cough sedation for surgical procedure and bronchoscopy. Butamirate is well tolerated. In rare cases, skin rash, nausea, diarrhea, dizziness have been reported.They disappear after reduction of the dosage or discontinuation of the drug.

Bunaftine is a class III antiarrhythmic agent which has been found effective in treating or preventing both ventricular and supraventricular arrhythmias. The acute electrophysiologic effects of intravenous Bunaphtine 1,5 mg/kg body weight, were studied in 19 subjects with estimated normal impulse formation and conduction. Significant effects were sinus bradycardia, prolongation of atrial refractory periods, depression of intranodal and infranodal conduction and prolongation of His-Purkinje system refractory periods. These properties are compared with those of amiodarone and quinidine and form the basis for correct use of Bunaphtine in the management of arrhythmias

Deptropine citrate is a well-known H1-histamine receptor antagonist and muscarinic receptor antagonist. It is prescribed frequently for treatment of asthma, although there has been a sharp decrease in prescriptions since 1994. Deptropine is gradually being replaced by inhaled beta 2 adrenergic agonists and glucocorticosteroids as the preferred clinical prescription. Recently deptropine has garnered interest as a potential treatment for breast cancer. In vitro studies have shown deptropine citrate has inhibitory effects on cell viability and mammosphere formation in Breast Cancer Stem Cells (BCSCs). However, it does not seem to inhibit the self-renewal capacity of the breast cancer cell line MDA-MB-231 when it is enriched with Cancer Stem Cells.

Sediel (generic name: tandospirone citrate, marketed as Sediel in Japan) is a new type of antianxiety drug developed independently by Sumitomo Pharmaceuticals. It acts selectively on only the serotonin nerves in the brain that play an important part in the formation of anxiety and depression, and demonstrates antianxiety and anti-depression effects. Since it does not act on the other nerves that are so extensive in the brain, there is virtually no hypnotic or sedative effect, and the drug displays virtually no drug-dependence or side effects such as drowsiness and dizziness. Sediel has been on sale in Japan since December 1996, and is recognized for recognized as effective in the treatment of generalized anxiety disorders. Tandospirone acts as a potent and selective 5-HT1A receptor partial agonist. It was also investigated the usefulness of 5-HT1A agonists for enhancing some types of cognitive performance and possibly social and work function in patients with schizophrenia, and related to this was discovered, that tandospirone in combination with atypical antipsychotic drugs can improve cognitive function in Schizophrenia.

Proxazole Citrate is a spasmolytic papaverine-like agent used for functional gastrointestinal disorders in veterinary and acute renal insufficiency. In animal models, Proxazole has antitussive, antispasmodic, analgesic, anti-inflammatory, and antipyretic activities. Proxazole has veterinary uses against gastritis, infective and non-infective gastro-enteritis, urethritis, cystitis and spastic states with an inflammatory component of the smooth muscles of the digestive and genito-urinary systems. Proxazole is excreted both in feces and urine mainly as inactive metabolites.

Clomiphene (CLOMID®) is a triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. It is an orally administered, nonsteroidal, ovulatory stimulant. Clomiphene (CLOMID®) is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)] containing between 30% and 50% of the cis-isomer. Clomiphene (CLOMID®) initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomiphene therapy is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis, resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.